{
  "directed": true,
  "multigraph": true,
  "graph": {
    "pybel_version": "0.13.0",
    "document_metadata": {
      "copyright": "Copyright © 2018 Fraunhofer Institute SCAI, All rights reserved.",
      "licenses": "CC BY 4.0",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "name": "Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation",
      "version": "1.0.0",
      "authors": "Sandra Spalek",
      "description": ""
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns",
      "DRUGBANK": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns",
      "ECCODE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns",
      "INTERPRO": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns",
      "MIRBASE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns",
      "NCBIGENE": "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns",
      "PFAM": "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns",
      "CTO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns",
      "DO": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns",
      "HP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns",
      "SCOMP": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns",
      "SFAM": "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"
    },
    "namespace_pattern": {
      "DBSNP": "rs[0-9]+",
      "TAXONOMY": "^\\d+$",
      "UNIPROT": "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\\.\\d+)?$",
      "PUBCHEM": "^\\d+$"
    },
    "namespaces_uncached": [],
    "annotation_url": {
      "Anatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno",
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "Cell": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno",
      "Confidence": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno",
      "Disease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno",
      "Gender": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno",
      "Subgraph": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno",
      "TextLocation": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
    },
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_list": {},
    "path": "/Users/cthoyt/dev/knowledge/hbp_knowledge/paris2013.bel"
  },
  "nodes": [
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "Anatabine",
      "id": "c77d4080804731f0ef07ad52ed2fbccdac5d02fb2620d8800d273e925feebcbf90b94a2399efeb42a91e65413550e0f713cd431329129e1cdd90329cae6b3ff6"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "lipopolysaccharide",
      "id": "66bc1a5b41c832a7d7b4b61aa44aae11a4bb778b350f17f7386e2f2a86365ef3007d5e07af494b32cae117170398c1fe5b5ee0e0e95bcef83eede21157e23d04"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "nicotine",
      "id": "81813864e07e0e955a0ccf7e9ec2430ce5cdbeae237c18991897f8314b29bdb2d0985dedfa71377ab67541fbcea0567e323d0cf47a5517efc83a67ac442abdb8"
    },
    {
      "function": "Abundance",
      "namespace": "CHEBI",
      "name": "stattic",
      "id": "666bba259afbf51d9a8368c8372d99b54bca24bd9bb2f3ca25a98b5900f457f624a2ca2b3ad0eeed72600cfa4682dbfd36d3dc40991b6a7affcfd55e4dfcf362"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "alpha7 Nicotinic Acetylcholine Receptor",
      "id": "24bfa0a4dedd705b999b510936aa1c989978fdeec807bf3046bd5178bd8e69ebbf2b1d2d2cd30ce5df8058656f59f497172cea193c9743a405bfb38be1aac50b"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Blood",
      "id": "7ac97258e1018ad54ed87da212efbe7d0f3bb62aaa4a4dfb15310905681edb01b03f65468f85e9b5499c0592920c16ac7c4bcf369d0c792ea4d155929790fd0f"
    },
    {
      "function": "Abundance",
      "namespace": "MESH",
      "name": "Microglia",
      "id": "02b5c9d69be012bcb43f05ec21f3168522e7cb682e90a7956b198540388c2652cc63707a9400288a6cf9ac7fe288615986eafce8e609e0871e97885e133245f9"
    },
    {
      "function": "BiologicalProcess",
      "namespace": "GO",
      "name": "inflammatory response",
      "id": "422dfc2db00b1d942862470cbabe1e8312bf97b25050190db5ae19636adae95f4fa18c512574526825bd377b16c2278899435eb759e951ba850ad476e14f9900"
    },
    {
      "function": "Complex",
      "members": [
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "STAT3",
          "id": "3127bcd18ece964c797c6ae9fcf716d99ad750c12e3f8121f817efbbedc60af9639294ab059c32ef6101cef3ccd9abc934d90dc7ccdbe6dc3604773782f7bf97"
        },
        {
          "function": "Protein",
          "namespace": "HGNC",
          "name": "STAT3",
          "id": "3127bcd18ece964c797c6ae9fcf716d99ad750c12e3f8121f817efbbedc60af9639294ab059c32ef6101cef3ccd9abc934d90dc7ccdbe6dc3604773782f7bf97"
        }
      ],
      "id": "0176f01d08a782c2fc338796254b55a0d936629a216195ed4bb0727dbe28ef373428fbe63f38316b7fc70f8bf9c235640390016617846af852a666ae54ad088e"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "Anatabine",
          "id": "c77d4080804731f0ef07ad52ed2fbccdac5d02fb2620d8800d273e925feebcbf90b94a2399efeb42a91e65413550e0f713cd431329129e1cdd90329cae6b3ff6"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "lipopolysaccharide",
          "id": "66bc1a5b41c832a7d7b4b61aa44aae11a4bb778b350f17f7386e2f2a86365ef3007d5e07af494b32cae117170398c1fe5b5ee0e0e95bcef83eede21157e23d04"
        }
      ],
      "id": "01efb28e381e22fb50bc8795fbe15d1242ae0c7566d9e65f043bcb581d3c6b0a255c17f9dacca71a32e4600fcac1832c7d0f0a5f401f4ef8a242e2f4a7e9d886"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "Anatabine",
          "id": "c77d4080804731f0ef07ad52ed2fbccdac5d02fb2620d8800d273e925feebcbf90b94a2399efeb42a91e65413550e0f713cd431329129e1cdd90329cae6b3ff6"
        },
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "lipopolysaccharide",
          "id": "66bc1a5b41c832a7d7b4b61aa44aae11a4bb778b350f17f7386e2f2a86365ef3007d5e07af494b32cae117170398c1fe5b5ee0e0e95bcef83eede21157e23d04"
        },
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "Blood",
          "id": "7ac97258e1018ad54ed87da212efbe7d0f3bb62aaa4a4dfb15310905681edb01b03f65468f85e9b5499c0592920c16ac7c4bcf369d0c792ea4d155929790fd0f"
        }
      ],
      "id": "6000e04dd7453523363a467ba73941d1bbec8599d2e756a081e601c660c1cebbf6cec39aca761fa59e7aa5665a6648e6b52a2feda17f54fb55198df8f1504fc8"
    },
    {
      "function": "Composite",
      "members": [
        {
          "function": "Abundance",
          "namespace": "CHEBI",
          "name": "Anatabine",
          "id": "c77d4080804731f0ef07ad52ed2fbccdac5d02fb2620d8800d273e925feebcbf90b94a2399efeb42a91e65413550e0f713cd431329129e1cdd90329cae6b3ff6"
        },
        {
          "function": "Abundance",
          "namespace": "MESH",
          "name": "Blood",
          "id": "7ac97258e1018ad54ed87da212efbe7d0f3bb62aaa4a4dfb15310905681edb01b03f65468f85e9b5499c0592920c16ac7c4bcf369d0c792ea4d155929790fd0f"
        }
      ],
      "id": "c0fe34e92aea80875cad80ebd472ad66198a56d25de84998017d623309977b5b38e118aef13244fd0e7bdfba46b98fd77b6ebb386f29360914628f3c4e8db3cf"
    },
    {
      "function": "Protein",
      "namespace": "FPLX",
      "name": "NFkappaB",
      "id": "a76f3010d13c4b506ba95e6e6bef897dc400ea1bad5f8288ce4b084f2b57f9e7aa59f5146eff656ed56a6d2077d5907c41cbd4539f26d63411b79ffe7179e54a"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "IL1B",
      "id": "bd7736973dc00dadc09dff75214ff05344d2e9b6dfbc09a364f08b7cae84142149292551bd60d5addd6130e971c2ccd4c73b963ad918ad9b0a418b94e5a30cfd"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RELA",
      "id": "02493376083b06f6044a237f4e756f227621391970d2c53693da442582176f53d992abe2f0fd0b28f8a305ab5f3429be4b4d20bd7fd4302ae88cf1eb87fe7e40"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "RELA",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "d51b9a8eb62ec08dc863472ef97b53eab28965cccd38adc932c625c25bbe0a563c50d39c467cb8d3bef104cab2430c5701227bbd62143b608a4a5d4be54c25bc"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "STAT3",
      "id": "3127bcd18ece964c797c6ae9fcf716d99ad750c12e3f8121f817efbbedc60af9639294ab059c32ef6101cef3ccd9abc934d90dc7ccdbe6dc3604773782f7bf97"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "STAT3",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "e77397464fb83748a7286fed66311fda660971f8d0f47f6e1290ea5f6857bdf68d361fd34f0055467a45dd0e21d8008bba9648e146ffd83670ee544b04bcf8d4"
    },
    {
      "function": "Protein",
      "namespace": "HGNC",
      "name": "TNF",
      "id": "a262f5edbfb734dd0ec9696a3b78644fccfb4054a9cf9225beb17c33ef416a75809ff59ec1646e29a3cccc804c9294f8d2c48120af9f5ee98e764a584626426d"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Il1b",
      "id": "687adaa5d38b87eb816cf53120a115fe59e0725752db5823333edf76b86316cfc63ba90160f3f8c5d4e58c40863ff1dcb9e6c2c33f1e1e1fc68ecfec74c18aa4"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Il6",
      "id": "983c798fb52b7f489317dd256bd933192ace895af9f9060ca485035ee3a49567e3a15e5dadb01d8122be42cde2acb0b56a0e262776451bf9046220e03a995b0a"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Stat3",
      "id": "2b3cddef45c625b1aec1910089b2faed7063f63b337ca8dacc46af56ca0117780c34cef9c9a5585235a10d3c93e793d44df32caccb86b87e20ef8dd58daa17a4"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Stat3",
      "variants": [
        {
          "kind": "pmod",
          "identifier": {
            "namespace": "bel",
            "name": "Ph"
          }
        }
      ],
      "id": "05016cf00c9e4dcd7b9080bc5580699c475c98c535375dc6bd3e52d8e72fe2bfd84b860b4a2c3252bb9ea4bd849b1fcbb3e67168d8c5bf0d41828d08a719e28e"
    },
    {
      "function": "Protein",
      "namespace": "MGI",
      "name": "Tnf",
      "id": "a45cfec2fa122ac50a93a261bc8a06b78b1756617089bb7c55634a6f53f49a60f04f79884235d0da17620eedecf0a8422cc773f07b0dcabf7aad98cf3ebf0b72"
    },
    {
      "function": "Pathology",
      "namespace": "MESH",
      "name": "Alzheimer Disease",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541"
    }
  ],
  "links": [
    {
      "line": 85,
      "relation": "regulates",
      "evidence": "Nicotine has been shown to modulate inflammation by affecting STAT3 phosphorylation (Chatterjee et al., 2009; Hosur and Loring, 2011) and by opposing NFkB activation (Leite et al., 2010; Zhou et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "source": 2,
      "target": 7,
      "key": "b7212fb3cae11e957aff6dc23d047b2aa45861cf3cfb2e6a67b0b5ce44060c0dc9b6d2993093bab1fd8783c760bef581f10db233ce5a3353874b3bc6e4700806"
    },
    {
      "line": 86,
      "relation": "association",
      "evidence": "Nicotine has been shown to modulate inflammation by affecting STAT3 phosphorylation (Chatterjee et al., 2009; Hosur and Loring, 2011) and by opposing NFkB activation (Leite et al., 2010; Zhou et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "source": 2,
      "target": 17,
      "key": "e3ce7752a54c3d7d6934159d2447613644b733a86c53105bf3559126fd372d872d156a19d8e10ab63bc83e8eeaf664dd59cd4dbf287283d93672bf4e804b08d3"
    },
    {
      "line": 87,
      "relation": "decreases",
      "evidence": "Nicotine has been shown to modulate inflammation by affecting STAT3 phosphorylation (Chatterjee et al., 2009; Hosur and Loring, 2011) and by opposing NFkB activation (Leite et al., 2010; Zhou et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "object": {
        "modifier": "Activity"
      },
      "source": 2,
      "target": 12,
      "key": "5d14931dce2632dca8a3450d1a81d8a0c41c3dcd7250713b11a83207804d1733543869575df0d80b5281b484596396e07fa2b369eef7a6a4d9a95c05dcdcfaed"
    },
    {
      "line": 86,
      "relation": "association",
      "evidence": "Nicotine has been shown to modulate inflammation by affecting STAT3 phosphorylation (Chatterjee et al., 2009; Hosur and Loring, 2011) and by opposing NFkB activation (Leite et al., 2010; Zhou et al., 2010)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "source": 17,
      "target": 2,
      "key": "590bfebe8344ae3faa182e7d2984ae0e4234f318dd6fc73163c64cd393fea3dd97e348fb80863a8a31b99ab9d666528dcfd69d4ac785ffea783ae2b02232be37"
    },
    {
      "relation": "hasVariant",
      "source": 16,
      "target": 17,
      "key": "e39435c1348f217cc9cce7c925f90bd391da1bbc939ac4f4c08ca5c70e03100d1a8991a2f918452e95def9067c56d70330d08e862245632e0dbc00b78b74773a"
    },
    {
      "line": 98,
      "relation": "increases",
      "evidence": "Following this 15 mins of stimulation with TNFa, an increased p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, P=0.021) without a noticeable increase in STAT3 phosphorylation (Mann–Whitney U=7, Z=-0.289, P=0.773) was observed compared to the control conditions (Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 18,
      "target": 15,
      "key": "69c8fd1e3ae7a0b88872e3bc370e3d74202e2372e3a8f9bf4cb848474460b9d4b0e97a7f3000a4d0840e28389bc92036e97dba38c70681a88936ab9b5977ec9e"
    },
    {
      "line": 136,
      "relation": "increases",
      "evidence": "An increased in both STAT3 (Mann–Whitney U=0, Z=-2.309, P=0.021) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, P=0.021) was observed following 24 h of treatment with TNFa",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 18,
      "target": 15,
      "key": "da773a7d4f30da04617f969b1191bc852139efa2f1630479ba6d3e3add3fbea9be8d92e5b5416293e604965cf240efeb3271b89474d23b4298181acdbaf74296"
    },
    {
      "line": 221,
      "relation": "increases",
      "evidence": "TNFa significantly stimulated STAT3 (Mann–Whitney U=0, Z=-2.309, P=0.021) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, P=0.021)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "HEK293": true
        }
      },
      "source": 18,
      "target": 15,
      "key": "e97a209d386712fd372e8f1ab8986ce7b19efd940ebc051a32e89045b84ea2d2b0030958e4a5abea6eae06e61219990655a55c149d6bccffd631c55556bb7e93"
    },
    {
      "line": 99,
      "relation": "causesNoChange",
      "evidence": "Following this 15 mins of stimulation with TNFa, an increased p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, P=0.021) without a noticeable increase in STAT3 phosphorylation (Mann–Whitney U=7, Z=-0.289, P=0.773) was observed compared to the control conditions (Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 18,
      "target": 17,
      "key": "8e5399d372331fcfe6754dcfd96c1c558e3380a87b72fad3a202b61c7be00eaf3b81344f6d8c2de4fb0136fd628239f7d69ed99b484afc53fca5dd759f98bcfa"
    },
    {
      "line": 137,
      "relation": "increases",
      "evidence": "An increased in both STAT3 (Mann–Whitney U=0, Z=-2.309, P=0.021) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, P=0.021) was observed following 24 h of treatment with TNFa",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 18,
      "target": 17,
      "key": "f5edd82877aa09f40ea572c85d2b7d00c21ff57a2ba9d96aa93106a6be94c174d2602ca0cfec78c86dc333857205d8698f44f370b371447082357537a24890f9"
    },
    {
      "line": 222,
      "relation": "increases",
      "evidence": "TNFa significantly stimulated STAT3 (Mann–Whitney U=0, Z=-2.309, P=0.021) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, P=0.021)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "HEK293": true
        }
      },
      "source": 18,
      "target": 17,
      "key": "d32bf87e83522f4b998a1e72f7f46875cbebe41fc9585033285206d0a71eb9ebdfc9e94c580c2328334c221d36bdd0dfda26fede35d59fe44465ba47e5b3ed70"
    },
    {
      "relation": "hasVariant",
      "source": 14,
      "target": 15,
      "key": "3fcf9da549a1e7a9932a20769eafaaf5b64e9fa82b38b57bfa5734d49332c3ae8fb40859085e8f970f49a15de4df46fa920124a4ddee2238ca6b91cb996401b3"
    },
    {
      "line": 108,
      "relation": "decreases",
      "evidence": "We observed that anatabine inhibits basal STAT3 phosphorylation levels (Mann– Whitney U=0, Z=-2.882, P=0.004) and reduces the induction of p65 NFkB phosphorylation by TNFa (Mann–Whitney U=0, Z=-2.882, P=0.004) within this 15 min time-frame (Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "d2875e2300f3c9b1dbfb00c016164c25f7cb3b282bd050c3484f2244e2e0f8a09f0f6b330c09d4abd669d33a5d094b62e673ac7149305a8b1c246ab841724d5d"
    },
    {
      "line": 144,
      "relation": "decreases",
      "evidence": "Under these culture conditions, anatabine also inhibited both STAT3 and p65 NFkB phosphorylation induced by TNFa (Fig. 2)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "f485aa1e5566f95d3d4b6c5abde0480b8bee38bdf3f9c6af6284cdc321925988a925bd45521eae8fd05921a586c6a80601e41c201a9cc08c1b26a3ff1563a6e5"
    },
    {
      "line": 157,
      "relation": "decreases",
      "evidence": "A significant inhibition of STAT3 phosphorylation was observed with 600 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021) and with 800 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021) and a significant inhibition of p65 NFkB phosphorylation was observed with 600 mg/ml of anatabine (Mann–Whitney U=1.0, Z=-2.021, P=0.043) and with 800 mg/ml of anatabine (Mann–Whitney U=0,Z=-2.309, P=0.021)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "71fb8fd84e8916674e24905f6ad1e4b1759f93e689dabf3e39d978a55c7d3f58d5b3facc7e87e670998c8cd0230eca3c608537641774eda4d5493db0560c2e36"
    },
    {
      "line": 182,
      "relation": "decreases",
      "evidence": "We observed that anatabine significantly suppressed the stimulation of p65 NFkB and STAT3 phosphorylation by LPS in microglia (Fig. 3)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "dc8ae4f610102f09e7407a6693ed60bf4139895735e40bcdca3a61f07dfe5e573fbb6664be0c626bfc73f14740e97f0d3e19e98287438f180562cc9d97622901"
    },
    {
      "line": 191,
      "relation": "decreases",
      "evidence": "Kruskal–Wallis test revealed that doses of anatabine significantly suppressed both LPS induced STAT3 phosphorylation (H=15.658, df=4, P=0.005) and p65 NFkB phosphorylation (H=14.150, df=4, P=0.007) in human microglia",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "d059ee581987ab9080b66a5b4b233beca96b3de9b860c7544a8788a59662d6c7f73031e9f0acdfae642440d68a1840239fff5f026f04c4eef9b13f5c13297a89"
    },
    {
      "line": 203,
      "relation": "decreases",
      "evidence": "A significant inhibition of STAT3 phosphorylation was observed with 10 mg/ml of anatabine (Mann–Whitney U=1, Z=-2.021, P=0.043), with 100 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021), with 300 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021) and with 600 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "2a591968919fc8ca6dde029f139851e37c2c88246a6cff2c1e82a5714c96c6ed9470e392c71046c5b419f3354941d09f89678bd5e586b3740ae8f4f4a61f3570"
    },
    {
      "line": 232,
      "relation": "decreases",
      "evidence": "An inhibition of TNFa induced STAT3 (Mann–Whitney U=0, Z=-2.121, P=0.034), and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.121, P=0.034) was observed in these cells following the anatabine treatment (Fig. 4) suggesting that anatabine may also mediate its anti-inflammatory activity independently of nicotinic acetylcholine receptor expression",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "HEK293": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "b41f0b52bd4ca52e9c8bf912119b0faa0ac16dc9f283a49ad073a1028d0918e93fb50a52544b516a873b92ee95748334865d824470d360023999ddc407769838"
    },
    {
      "line": 262,
      "relation": "decreases",
      "evidence": "Anatabine appears to completely antagonize LPS induced STAT3 (Mann–Whitney U=0, Z=-3.077, P=0.002) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-3.077, P=0.002) in human mononuclear cells",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "mononuclear cell": true
        }
      },
      "source": 0,
      "target": 17,
      "key": "871f1e8692b81880422ba647be3a28345a0a16ed819b0f5611beaacf1c37c107f98fc3049167a6164b0c6b5a8739ef55b7b15de6f745f707a8ed7b79277a5c0f"
    },
    {
      "line": 109,
      "relation": "decreases",
      "evidence": "We observed that anatabine inhibits basal STAT3 phosphorylation levels (Mann– Whitney U=0, Z=-2.882, P=0.004) and reduces the induction of p65 NFkB phosphorylation by TNFa (Mann–Whitney U=0, Z=-2.882, P=0.004) within this 15 min time-frame (Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "a81c015b29272efff753a34f88bb46123dac289f1d456c906b30b99eb3f96461bf74db13bbed1e5e50f0781806782c83ac3f5986e1078b88b5f6b92e4e94bf8d"
    },
    {
      "line": 145,
      "relation": "decreases",
      "evidence": "Under these culture conditions, anatabine also inhibited both STAT3 and p65 NFkB phosphorylation induced by TNFa (Fig. 2)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "599422367f32ba8fd89128e42b3306557f554786e28ad49c716ed718cf061682684d20a25cb954b2fae9be58ef5b40c295e790eae82a3d0a5f40e3d24ae285b6"
    },
    {
      "line": 158,
      "relation": "decreases",
      "evidence": "A significant inhibition of STAT3 phosphorylation was observed with 600 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021) and with 800 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021) and a significant inhibition of p65 NFkB phosphorylation was observed with 600 mg/ml of anatabine (Mann–Whitney U=1.0, Z=-2.021, P=0.043) and with 800 mg/ml of anatabine (Mann–Whitney U=0,Z=-2.309, P=0.021)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "a612966fd0926dc32d211eabdf3a20f9e0b0c36ab694a078cca8d91dd74439e7dcea9eb605c22165043b602f32ea0e1e13213559fcfb9a045bc8bea033bdcc1f"
    },
    {
      "line": 184,
      "relation": "decreases",
      "evidence": "We observed that anatabine significantly suppressed the stimulation of p65 NFkB and STAT3 phosphorylation by LPS in microglia (Fig. 3)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "c244420508cb6409cc8854721b74d75d5a8a87859a06db286b812f9689c8c1ce71fd838e4eda4d1cd9e2bd2d379c811e7a12069589bc629beae45bbd94e50fae"
    },
    {
      "line": 192,
      "relation": "decreases",
      "evidence": "Kruskal–Wallis test revealed that doses of anatabine significantly suppressed both LPS induced STAT3 phosphorylation (H=15.658, df=4, P=0.005) and p65 NFkB phosphorylation (H=14.150, df=4, P=0.007) in human microglia",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "5534e6dab28fe13fddb7fc7a35859c258402f163f362c9abbcef490f9b0f20db38ec9585960efc50401924b3c1061d4814a80bda7f97c591ab46732613674920"
    },
    {
      "line": 214,
      "relation": "decreases",
      "evidence": "Similarly, LPS induced p65 NFkB phosphorylation in microglia was significantly inhibited with 10 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021), with 100 mg/ml of anatabine (Mann– Whitney U=0, Z=-2.309, P=0.021), with 300 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "10514113c9057355b0730d2f9f2beb24fd5ced0e05ad5b5b35a513a280d4426597c2b91fee80498494f5b62423b321da34c2a32f76e51c3a2215c109ebb03efe"
    },
    {
      "line": 233,
      "relation": "decreases",
      "evidence": "An inhibition of TNFa induced STAT3 (Mann–Whitney U=0, Z=-2.121, P=0.034), and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.121, P=0.034) was observed in these cells following the anatabine treatment (Fig. 4) suggesting that anatabine may also mediate its anti-inflammatory activity independently of nicotinic acetylcholine receptor expression",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "HEK293": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "8e9ac4a0250f0f56e941445e5f915de25889535b85186d4b8e1dc42a10ccbad5be71800dbe0cf1a0f4289849495e85c62ac53e8f5a508a6d0c5d477d3b117b41"
    },
    {
      "line": 261,
      "relation": "decreases",
      "evidence": "Anatabine appears to completely antagonize LPS induced STAT3 (Mann–Whitney U=0, Z=-3.077, P=0.002) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-3.077, P=0.002) in human mononuclear cells",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "mononuclear cell": true
        }
      },
      "source": 0,
      "target": 15,
      "key": "56f4c39b0575fe2e91842baa4a85e5a92a2e31f37b86b8d02f7c235425d552823f337fcfa8a4dbb447b6b16e0caad3c7a7e153c3d0e9eb375be058197d2a5bee"
    },
    {
      "line": 234,
      "relation": "regulates",
      "evidence": "An inhibition of TNFa induced STAT3 (Mann–Whitney U=0, Z=-2.121, P=0.034), and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.121, P=0.034) was observed in these cells following the anatabine treatment (Fig. 4) suggesting that anatabine may also mediate its anti-inflammatory activity independently of nicotinic acetylcholine receptor expression",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "HEK293": true
        }
      },
      "source": 0,
      "target": 7,
      "key": "4bca24d9ab4a52dc8efd96f6e570d05481196a7820220847d7c2e9a869de74ae331dbc27896144cfa5287c15911c531950230101b5096943501a1c317dacf951"
    },
    {
      "line": 335,
      "relation": "decreases",
      "evidence": "Western-blot experiments revealed that LPS significantly stimulated of STAT3 phosphorylation in the spleen (Mann–Whitney U=0, Z=-2.309, P=0.021) (Fig. 8) and kidney (Mann–Whitney U=0, Z=-2.882, P=0.004) (data not shown) whereas anatabine significantly inhibited STAT3 phosphorylation in the spleen (Mann–Whitney U=1, Z=-2.021, P=0.043) and kidney (Mann– Whitney U=5, Z=-2.082, P=0.037) (data not shown)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true,
          "Kidney": true
        }
      },
      "source": 0,
      "target": 22,
      "key": "1eed4d58db084daae98fc86178aaa976b63eb2923103c63a3a339938a332d998c4cbc1f1d188df277aeeff721fbddc461a7e9867ddaaf6ee8e6a0d73cfab5d32"
    },
    {
      "line": 366,
      "relation": "decreases",
      "evidence": "A significant elevation of STAT3 phosphorylation was detected in the brain of Tg APPsw compared to their control littermates (Mann–Whitney U=1, Z=-3.767, p<0.001) and a significant reduction in STAT3 phosphorylation (Mann–Whitney U=8, Z=-2.066, p=0.039) was observed in the brain of Tg APPsw treated with anatabine compared to untreated Tg APPsw littermates (Fig. 10).",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 0,
      "target": 22,
      "key": "455c10c4dbadca41a83326afde045538b1b617147eb0263d45a8e8a7bda93203bd333a43deddb0cf6c5bea782ef8b544f954a04b9eac7ccc0f8cf105f9091c3c"
    },
    {
      "line": 354,
      "relation": "decreases",
      "evidence": "Following 90 days of treatment with anatabine, a significant reduction in brain TNF-a (Mann–Whitney U=6, Z=-2.146, p=0.032) and in IL-6 (Mann–Whitney U=0, Z=-2.887, p=0.004) was observed in Tg APPsw mice compared to Tg APPsw that received regular drinking water (Fig. 9)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 0,
      "target": 23,
      "key": "1023be99368a5ba07ce3ac4e5246da7c88455903d3326f94f4c09800935324844fa0c6ca68272f7e0385ed0af9ecfd4b5f2b83ab128313d081dac2d755d0408b"
    },
    {
      "line": 355,
      "relation": "decreases",
      "evidence": "Following 90 days of treatment with anatabine, a significant reduction in brain TNF-a (Mann–Whitney U=6, Z=-2.146, p=0.032) and in IL-6 (Mann–Whitney U=0, Z=-2.887, p=0.004) was observed in Tg APPsw mice compared to Tg APPsw that received regular drinking water (Fig. 9)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 0,
      "target": 20,
      "key": "17804d1f8f796a24aee157f33759b3777b7d5a95b19a953e53f6c6492a59cb9af1fcc67133e4923d738b95247f6dfe14ca6ce3a7b76444a270469f53f49aff1b"
    },
    {
      "line": 115,
      "relation": "decreases",
      "evidence": "As a positive control, we used stattic, a known inhibitor of STAT3 dimerization and phosphorylation",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 3,
      "target": 17,
      "key": "100b041937d9dd8f200a1cd5d536843c73040e545fbe5b68bf3c936eb19a6e737a120174dce692bd9db2209a3bdaad734fe18a0bc510df7d6b1f7561dfcfbef3"
    },
    {
      "line": 125,
      "relation": "decreases",
      "evidence": "We found that stattic inhibited STAT3 phosphorylation (Mann–Whitney U=0, Z=-2.324, P=0.02) and also suppressed p65 NFkB phosphorylation (Mann–Whitney U¼0, Z¼\u00022.324, P¼0.02) mimicking the effect of anatabine in SHSY5Y cells (Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 3,
      "target": 17,
      "key": "df870c3fc5ceb66d4324eed687ecb0238898ea55fc9b02b3741d8858cac2ddfdda47d1605f67e1200aa963bbc5e9facd476bbe36bdffb2f3565031dd0a1b79c2"
    },
    {
      "line": 116,
      "relation": "decreases",
      "evidence": "As a positive control, we used stattic, a known inhibitor of STAT3 dimerization and phosphorylation",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 3,
      "target": 8,
      "key": "4be6aefcaa6cf570d62e86f677e16798a9a3dc02a6ada8432d038a56ab9710bba645e3c5966903f5fd2b3791ee267004b814ffbce51f1a32d15b1c436423bbf6"
    },
    {
      "line": 126,
      "relation": "decreases",
      "evidence": "We found that stattic inhibited STAT3 phosphorylation (Mann–Whitney U=0, Z=-2.324, P=0.02) and also suppressed p65 NFkB phosphorylation (Mann–Whitney U¼0, Z¼\u00022.324, P¼0.02) mimicking the effect of anatabine in SHSY5Y cells (Fig. 1)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        }
      },
      "source": 3,
      "target": 15,
      "key": "bb46a2cd8cd9fd88c4f73be41ea395717b524f4ed742ecef4913f95306de55be406e7e47320679c8f4f428f6d9b2233a34c9525b0d2a280c8eeca2474bde2d61"
    },
    {
      "relation": "hasComponent",
      "source": 8,
      "target": 16,
      "key": "fd3a1c1db530d270820b372ccc0911fd9a38fea5d3ee01c6a5fa0fd42f88f63a6a921b2d07806c99d23300ceaf0031c92e740398443de2ed56193d02f9430002"
    },
    {
      "line": 166,
      "relation": "increases",
      "evidence": "We next tested the impact of anatabine on STAT3 and p65 NFkB phosphorylation induced by a 24 h treatment with LPS on human microglial cells, a cell type known to express alpha7-nicotinic acetylcholine receptor subtype (Suzuki et al., 2006)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 6,
      "target": 4,
      "key": "bded399c353707cab55d5613d6961c9374e8bcc9d2619e7d5c099ec7189848295e2a05b07d916ad0b5f42a53c7caaf3e6c31dc18237f1279a80d6c472be08c2c"
    },
    {
      "line": 174,
      "relation": "increases",
      "evidence": "An increased STAT3 (Mann–Whitney U=0, Z=-2.309, P=0.021) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, p=0.021) was observed in LPS treated microglia (Fig. 3)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 1,
      "target": 17,
      "key": "6fe8598484306506da9f281eb67d4f8c88351e5cf0bb0fb7f0c9c2130ba6646b0ea7634de4c19663b5f101d37bcc163914d83592d8377fe9adcee80b4f2e4152"
    },
    {
      "line": 181,
      "relation": "increases",
      "evidence": "We observed that anatabine significantly suppressed the stimulation of p65 NFkB and STAT3 phosphorylation by LPS in microglia (Fig. 3)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 1,
      "target": 17,
      "key": "31e766acc34cc3c9ed94fc14f02cc2a82fdee3f945a8750fd4f92de8ee543c78f5e468ba96befcbe2db6fe8a737e5fd8d9272daba9f880a42361e61cfdf6f1fe"
    },
    {
      "line": 254,
      "relation": "increases",
      "evidence": "Following a 24 h incubation with LPS, a significant stimulation of STAT3 (Mann– Whitney U=0, Z=-2.882, P=0.004) and p65 NFkB phosphorylation was observed (Mann–Whitney U=1, Z=-2.722, P=0.006)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "mononuclear cell": true
        }
      },
      "source": 1,
      "target": 17,
      "key": "3be2ae81db34132996473b418f01470bf79a1a01118639286c9d78fed99391053862f62f7bffab1867d1a2d0e4c0769e340fb63483007ba1d0af62ead0bda954"
    },
    {
      "line": 175,
      "relation": "increases",
      "evidence": "An increased STAT3 (Mann–Whitney U=0, Z=-2.309, P=0.021) and p65 NFkB phosphorylation (Mann–Whitney U=0, Z=-2.309, p=0.021) was observed in LPS treated microglia (Fig. 3)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 1,
      "target": 15,
      "key": "f9dfae9b6c09a2ce6f494017ea0401d327d7a8e8888d262c644f071808e561b53e6c25edda0c93eca3496e15fcc1c842aa1db4b9e01e0ccd5a963ba7bd6a27f2"
    },
    {
      "line": 183,
      "relation": "increases",
      "evidence": "We observed that anatabine significantly suppressed the stimulation of p65 NFkB and STAT3 phosphorylation by LPS in microglia (Fig. 3)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 1,
      "target": 15,
      "key": "9210119cd87282cc130ddd3ea63873672d4b61d71d0b3198899df9b6c1f3e7a860baecc6392082cb64f5b74b5a1571579ec6683878ede6c5632e3fe5c5347ed5"
    },
    {
      "line": 213,
      "relation": "increases",
      "evidence": "Similarly, LPS induced p65 NFkB phosphorylation in microglia was significantly inhibited with 10 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021), with 100 mg/ml of anatabine (Mann– Whitney U=0, Z=-2.309, P=0.021), with 300 mg/ml of anatabine (Mann–Whitney U=0, Z=-2.309, P=0.021)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "microglial cell": true
        }
      },
      "source": 1,
      "target": 15,
      "key": "58e977dafa333d352237be75b151ce43ae66bec09931542cbbb32b7bc743ed1ea356291214038b65f3073e2992bdbf0606aec352e13d4e6a7809aa7555bbcf2c"
    },
    {
      "line": 253,
      "relation": "increases",
      "evidence": "Following a 24 h incubation with LPS, a significant stimulation of STAT3 (Mann– Whitney U=0, Z=-2.882, P=0.004) and p65 NFkB phosphorylation was observed (Mann–Whitney U=1, Z=-2.722, P=0.006)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Cell": {
          "mononuclear cell": true
        }
      },
      "source": 1,
      "target": 15,
      "key": "e54e932230b926016c7c5ec7dd657400827be31fd9847742adc51afd38fb3dc0b297f01556e9ca636ad402e1170d5f7b8b660841db49ab415e126efc6159804b"
    },
    {
      "line": 241,
      "relation": "increases",
      "evidence": "Anatabine at 200 mg/ ml significantly lowered LPS induced IL-1b levels in whole blood (Mann–Whitney U=0.0, Z=-2.3, P=0.02)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "source": 1,
      "target": 13,
      "key": "bb0043e7be555d666c0523fe82f8575e1a6abec87ce85eebfef934e0093ec6d92a310a15d4a635dac993da7038a7b83248de25760992618558da9ca046a5f86d"
    },
    {
      "line": 273,
      "relation": "increases",
      "evidence": "Our results showed that intraperitoneal injection of LPS (1 mg/kg) caused a significant elevation of plasma IL-1b (Mann–Whitney U=3, Z=-2.988, P=0.003), IL-6 (Mann–Whitney U=0, Z=-3.366, P=0.001) and TNFa (Mann– Whitney U=0, Z=-3.508, P<0.001) 4 h after the LPS challenge whereas in mice co-treated with an intraperitoneal injection of anatabine (2 mg/kg) and LPS, a significant reduction in plasma IL-1b (Mann–Whitney U=7, Z=-2.645, P=0.008) and TNFa (Mann–Whitney U=4, Z=-2.941, P=0.003) levels was observed (Fig. 6)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Plasma": true
        }
      },
      "source": 1,
      "target": 19,
      "key": "b2e275e7cbbca0442ddedaab98fae24541b91109d3fee8c472be86966650c3d3763aef9bcf3ca1e65009652269462b0d5fc0b5fff9f3e2fb2e86b05f384e0012"
    },
    {
      "line": 291,
      "relation": "increases",
      "evidence": "An elevation of IL-6 (Mann–Whitney U=0, Z=-3.487, P<0.001), IL1b (Mann– Whitney U=0, Z=-3.24, P=0.001) and TNFa (Mann–Whitney U=0, Z=-3.361, P=0.001) was observed in the spleen of LPS challenged mice (Fig. 7)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true
        }
      },
      "source": 1,
      "target": 19,
      "key": "d7da17fe73ab784ad7b1f855c5d54a4453235a7f5233aceab29889e4879cfc6688d7f369ff12f2858d257cd381ceb998bf1034d664d89eaa68614e7c02f3ed25"
    },
    {
      "line": 311,
      "relation": "increases",
      "evidence": "Similarly, IL-1b (Mann–Whitney U=0, Z=-3.098, P=0.002), IL-6 (Mann–Whitney U=0, Z=-3.363, P<0.001) and TNF-a levels (Mann–Whitney U=0, Z=-3.361, P=0.001) were elevated in the kidney following the LPS challenge (data not shown)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Kidney": true
        }
      },
      "source": 1,
      "target": 19,
      "key": "89075a3a1228087d100e25f6c0a9654a4270d8b49fc8cf1eba3fcbbabfce4dcaa379f848040237815c0dc35a08b5d09e9c4b06a9df3859a2d4f0caa0d221b953"
    },
    {
      "line": 274,
      "relation": "increases",
      "evidence": "Our results showed that intraperitoneal injection of LPS (1 mg/kg) caused a significant elevation of plasma IL-1b (Mann–Whitney U=3, Z=-2.988, P=0.003), IL-6 (Mann–Whitney U=0, Z=-3.366, P=0.001) and TNFa (Mann– Whitney U=0, Z=-3.508, P<0.001) 4 h after the LPS challenge whereas in mice co-treated with an intraperitoneal injection of anatabine (2 mg/kg) and LPS, a significant reduction in plasma IL-1b (Mann–Whitney U=7, Z=-2.645, P=0.008) and TNFa (Mann–Whitney U=4, Z=-2.941, P=0.003) levels was observed (Fig. 6)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Plasma": true
        }
      },
      "source": 1,
      "target": 20,
      "key": "cb7047edbdfa609734d0079a2bee2cb6d8972e3fa7135ad6690db63f5b5193316cc476b029031bb4cc02b502efc055a3189a093805e5f407d5d2c9b73df363b7"
    },
    {
      "line": 292,
      "relation": "increases",
      "evidence": "An elevation of IL-6 (Mann–Whitney U=0, Z=-3.487, P<0.001), IL1b (Mann– Whitney U=0, Z=-3.24, P=0.001) and TNFa (Mann–Whitney U=0, Z=-3.361, P=0.001) was observed in the spleen of LPS challenged mice (Fig. 7)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true
        }
      },
      "source": 1,
      "target": 20,
      "key": "661620ac620b8167a44d6a7c70bc101a1e9b97933a556a1146619a85ac1376dd08b042c3cac06818e49958d2bf7180188a02655621f19594e03687bffeab6410"
    },
    {
      "line": 312,
      "relation": "increases",
      "evidence": "Similarly, IL-1b (Mann–Whitney U=0, Z=-3.098, P=0.002), IL-6 (Mann–Whitney U=0, Z=-3.363, P<0.001) and TNF-a levels (Mann–Whitney U=0, Z=-3.361, P=0.001) were elevated in the kidney following the LPS challenge (data not shown)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Kidney": true
        }
      },
      "source": 1,
      "target": 20,
      "key": "6df75deee2f7c816c4e288820485e05c0699fdc16f4e1a6115fbaf70e81185566dd28d355bb074e35797a295d95a7e5978f71c5a72a4001d1ecc72cb1f7cda0f"
    },
    {
      "line": 275,
      "relation": "increases",
      "evidence": "Our results showed that intraperitoneal injection of LPS (1 mg/kg) caused a significant elevation of plasma IL-1b (Mann–Whitney U=3, Z=-2.988, P=0.003), IL-6 (Mann–Whitney U=0, Z=-3.366, P=0.001) and TNFa (Mann– Whitney U=0, Z=-3.508, P<0.001) 4 h after the LPS challenge whereas in mice co-treated with an intraperitoneal injection of anatabine (2 mg/kg) and LPS, a significant reduction in plasma IL-1b (Mann–Whitney U=7, Z=-2.645, P=0.008) and TNFa (Mann–Whitney U=4, Z=-2.941, P=0.003) levels was observed (Fig. 6)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Plasma": true
        }
      },
      "source": 1,
      "target": 23,
      "key": "be7a3ca384387a373043da069b19257754f7e9870fc00c6366ab10247f6e5c4bdd110d2d50feab801e9d74d477988a0e1c008f05828488248e10d819b501f6eb"
    },
    {
      "line": 293,
      "relation": "increases",
      "evidence": "An elevation of IL-6 (Mann–Whitney U=0, Z=-3.487, P<0.001), IL1b (Mann– Whitney U=0, Z=-3.24, P=0.001) and TNFa (Mann–Whitney U=0, Z=-3.361, P=0.001) was observed in the spleen of LPS challenged mice (Fig. 7)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true
        }
      },
      "source": 1,
      "target": 23,
      "key": "195b05c92acb0d785a55429a7465d278bde0a5968cb8fc8aa5434a0e5218907c5c7be9843cf784892013e633aa1f81a88bbe5cd20bf9a6c2f29dee4ac5411c02"
    },
    {
      "line": 313,
      "relation": "increases",
      "evidence": "Similarly, IL-1b (Mann–Whitney U=0, Z=-3.098, P=0.002), IL-6 (Mann–Whitney U=0, Z=-3.363, P<0.001) and TNF-a levels (Mann–Whitney U=0, Z=-3.361, P=0.001) were elevated in the kidney following the LPS challenge (data not shown)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Kidney": true
        }
      },
      "source": 1,
      "target": 23,
      "key": "7b376844a174cea6bb4784e070f68cfb3b7e855da1a3b39927047c52ece782f4ce54d82d516e06babe5c5b52ca5f5b608218c5bf2f4827874405d300d0e195aa"
    },
    {
      "line": 334,
      "relation": "increases",
      "evidence": "Western-blot experiments revealed that LPS significantly stimulated of STAT3 phosphorylation in the spleen (Mann–Whitney U=0, Z=-2.309, P=0.021) (Fig. 8) and kidney (Mann–Whitney U=0, Z=-2.882, P=0.004) (data not shown) whereas anatabine significantly inhibited STAT3 phosphorylation in the spleen (Mann–Whitney U=1, Z=-2.021, P=0.043) and kidney (Mann– Whitney U=5, Z=-2.082, P=0.037) (data not shown)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true,
          "Kidney": true
        }
      },
      "source": 1,
      "target": 22,
      "key": "bf2c4f338e6ff67df64e3e8b3c0b994423fa32560427f0b869365d44ed2e0bf9a9ebff3020e6262e316533548b5df7ef8f5ff27cc47cac3405fb300691ba9550"
    },
    {
      "relation": "hasComponent",
      "source": 11,
      "target": 0,
      "key": "2791e9dc5e4c2fbf6a080176ac0f8e9f58f685f8f627b22c7a0d54b41ff3e3bee3e20d725c2cbab10642c3099a7db4df6db62e59b24ea30a7c242ce838974212"
    },
    {
      "relation": "hasComponent",
      "source": 11,
      "target": 5,
      "key": "5bd324c16c4836e21eee9cd7d1d3ecb2b886207ac6a309dcb0d44008c6f81ad5b9bb4617d7d34cff15cd041f35580dc7d2df7e5053d72f3a40a254554dd173b6"
    },
    {
      "line": 240,
      "relation": "decreases",
      "evidence": "Anatabine at 200 mg/ ml significantly lowered LPS induced IL-1b levels in whole blood (Mann–Whitney U=0.0, Z=-2.3, P=0.02)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "source": 11,
      "target": 13,
      "key": "2047f6fcacfa1dc8233b4b06493167baca471d82b9f2d4194915ce9c2ea56b65e2707cadd92ef895900b983908ff450ded92e36c82f352717ddd306476e94860"
    },
    {
      "relation": "hasComponent",
      "source": 10,
      "target": 0,
      "key": "7770a846adbbe7a3b128f524bf84491fa44dae899ef9e59cfe7bae770fddc7cad9d75b66db3c1ba2ddffea3934eb0a57e675c1c9fa78d85558ac42d671c22cf8"
    },
    {
      "relation": "hasComponent",
      "source": 10,
      "target": 1,
      "key": "388e89b2e9bea5d29b16bf120175c4eefad1427cf19da48649f23b6fc856f25014c145e83f0225ed9fb7ea7331493b057573e479c213ca80b16391d5d0afea27"
    },
    {
      "relation": "hasComponent",
      "source": 10,
      "target": 5,
      "key": "da5346857db2c632c0c8dabd87f312bdfd6f770deaa4ec70ce43d1a2d7a0c0b0fdc602dbfed5fc47fee7fa5a5d36ae1dadafbd92451a2298240f20f51cab44da"
    },
    {
      "line": 246,
      "relation": "decreases",
      "evidence": "Higher doses of anatabine resulted in a complete suppression of IL-1b levels in LPS challenged human blood (Mann–Whitney U=0.0, Z=-2.5, P=0.01)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "source": 10,
      "target": 13,
      "key": "f62875a85220aa2963d9e2b1245e7cc51c62e532602f80334a99f4672803a13d249754c4a8f740237c831d8fa96b2beafedb91bc52193403dbff14a312e093e2"
    },
    {
      "relation": "hasComponent",
      "source": 9,
      "target": 0,
      "key": "089a1ad10e41bafa5d0b93e44e80cbdf87172101d9e3366a598a6df2850e421260d60a2076c576c95ed1273046f37e5d654f23678a0f7a84571314f7a3f82dc7"
    },
    {
      "relation": "hasComponent",
      "source": 9,
      "target": 1,
      "key": "49332a04e4f98b0d560f1fec7c3694426b6e07bbcf9fac2f4ac418139aaa8e7bd6d9d72a71594d2ccd007c6bbc375b64f3942afd598b4e9732b36a3689cde9b1"
    },
    {
      "line": 276,
      "relation": "decreases",
      "evidence": "Our results showed that intraperitoneal injection of LPS (1 mg/kg) caused a significant elevation of plasma IL-1b (Mann–Whitney U=3, Z=-2.988, P=0.003), IL-6 (Mann–Whitney U=0, Z=-3.366, P=0.001) and TNFa (Mann– Whitney U=0, Z=-3.508, P<0.001) 4 h after the LPS challenge whereas in mice co-treated with an intraperitoneal injection of anatabine (2 mg/kg) and LPS, a significant reduction in plasma IL-1b (Mann–Whitney U=7, Z=-2.645, P=0.008) and TNFa (Mann–Whitney U=4, Z=-2.941, P=0.003) levels was observed (Fig. 6)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Plasma": true
        }
      },
      "source": 9,
      "target": 19,
      "key": "80ba51155c8631d3c7b75b927fecdeea3d6cc8c7973d499a63aca76b3dec316ce5ef70d1ca410ebd9fbf70b77a22bf8b39e0faf600337e120e7fd67b6eaa9dab"
    },
    {
      "line": 301,
      "relation": "decreases",
      "evidence": "Anatabine significantly inhibited LPS induced IL-6 (Mann–Whitney U=4, Z=-3.303, P=0.001), TNF-a (Mann–Whitney U=0, Z=-3.361, P=0.001) and IL-1b levels in the spleen (Mann–Whitney U=9, Z=-1.981, P=0.048) (Fig. 7)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true
        }
      },
      "source": 9,
      "target": 19,
      "key": "f71c4e67ff97838919b18fb466a9d832bd6d4e96db4a72ee97eedc4d6e878267de5de495a00280930048f124d1ca634f54f956f252a378f37b93eeed50f5c60e"
    },
    {
      "line": 277,
      "relation": "decreases",
      "evidence": "Our results showed that intraperitoneal injection of LPS (1 mg/kg) caused a significant elevation of plasma IL-1b (Mann–Whitney U=3, Z=-2.988, P=0.003), IL-6 (Mann–Whitney U=0, Z=-3.366, P=0.001) and TNFa (Mann– Whitney U=0, Z=-3.508, P<0.001) 4 h after the LPS challenge whereas in mice co-treated with an intraperitoneal injection of anatabine (2 mg/kg) and LPS, a significant reduction in plasma IL-1b (Mann–Whitney U=7, Z=-2.645, P=0.008) and TNFa (Mann–Whitney U=4, Z=-2.941, P=0.003) levels was observed (Fig. 6)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Plasma": true
        }
      },
      "source": 9,
      "target": 23,
      "key": "87c6184c08897bb19b073ee36fdd96e8844820b91a1d0bdce3810434c28c0055ccdb34f5f426b3e12def4a399ce643a7aaf02637e1ceee8d24faec2b8b774554"
    },
    {
      "line": 303,
      "relation": "decreases",
      "evidence": "Anatabine significantly inhibited LPS induced IL-6 (Mann–Whitney U=4, Z=-3.303, P=0.001), TNF-a (Mann–Whitney U=0, Z=-3.361, P=0.001) and IL-1b levels in the spleen (Mann–Whitney U=9, Z=-1.981, P=0.048) (Fig. 7)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true
        }
      },
      "source": 9,
      "target": 23,
      "key": "745539a3619dd266a36bc92079d298935514e2fa358a1818847780561584b6a57b65409030b4ab2768214718c32546ef1f6e0f5c6066cecb1536e29baeed7644"
    },
    {
      "line": 323,
      "relation": "decreases",
      "evidence": "A significant reduction in TNF-a (Mann–Whitney U=12, Z=-2.309, P=0.021) but no significant reduction in IL-6 levels (Mann–Whitney U=25, Z=-1.223, P=0.221) or IL-1b (Mann–Whitney U=8, Z=-1.857,P=0.063) were observed in the kidney of LPS and anatabine cotreated animals (data not shown)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Kidney": true
        }
      },
      "source": 9,
      "target": 23,
      "key": "2f8ab1bbb1ff08235efb8b5bbb6b4edb6f1bdc8877306825da60f5871d3385829767daf73cd171a9c46c92515dc357cdbbf451b9a2a3f926516488714098296d"
    },
    {
      "line": 284,
      "relation": "decreases",
      "evidence": "Plasma IL-6 levels show a trend for a reduction but were not significantly affected (Mann–Whitney U=19, Z=-1.368, P=0.171) by the anatabine treatment (Fig. 6)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Plasma": true
        }
      },
      "source": 9,
      "target": 20,
      "key": "3155111eb3fdcb85f5da26ae6622030382aec64289b51dcafe84772f88efb6a1df7dca0074e0b8e177b9ef78f08b5cdafa1e527f32cef490e2e97976c82ba9d7"
    },
    {
      "line": 302,
      "relation": "decreases",
      "evidence": "Anatabine significantly inhibited LPS induced IL-6 (Mann–Whitney U=4, Z=-3.303, P=0.001), TNF-a (Mann–Whitney U=0, Z=-3.361, P=0.001) and IL-1b levels in the spleen (Mann–Whitney U=9, Z=-1.981, P=0.048) (Fig. 7)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Spleen": true
        }
      },
      "source": 9,
      "target": 20,
      "key": "ab2b975c78b55086d5b9e6ec8cf5e19d44d49987d8cef877469d2a016646f07a560ffaef753162ac9f5bd7463a9d2bd60d57f7f9131bf2098857420ee35a7f06"
    },
    {
      "relation": "hasVariant",
      "source": 21,
      "target": 22,
      "key": "731f53d894765d3e16fdf4ecd4038d861cc4b17cbb00b5f581dd86f22bc0e7c5423725095ee8276bbc4dec5f2de5a34efd5946105e41de678e717eb553725c0a"
    },
    {
      "line": 343,
      "relation": "increases",
      "evidence": "An elevation of brain IL-6 (Mann–Whitney U=0, Z=-3, p=0.003) and TNF-a (Mann–Whitney U=0, Z=-2.887, p=0.004) was observed in Tg APPsw mice compared to their wild-type littermates (Fig. 9)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 24,
      "target": 20,
      "key": "fb5c3ea5bf5984908695bd6c85fceb1c1768b48dd3be44e36cb9ceb64766d3f618d0eb813f056d8a43391462f6e8a82e49e584cbaf536a3394a8d65370147a73"
    },
    {
      "line": 344,
      "relation": "increases",
      "evidence": "An elevation of brain IL-6 (Mann–Whitney U=0, Z=-3, p=0.003) and TNF-a (Mann–Whitney U=0, Z=-2.887, p=0.004) was observed in Tg APPsw mice compared to their wild-type littermates (Fig. 9)",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 24,
      "target": 23,
      "key": "bda6af22b997c0504663be2c6eae7f0f1ddd68ddb907ca172ff20e739f3a2dfb8ee7384d2c59c5f0374f8c28a54afdcf629603cec83c7be393e28931cc488081"
    },
    {
      "line": 365,
      "relation": "increases",
      "evidence": "A significant elevation of STAT3 phosphorylation was detected in the brain of Tg APPsw compared to their control littermates (Mann–Whitney U=1, Z=-3.767, p<0.001) and a significant reduction in STAT3 phosphorylation (Mann–Whitney U=8, Z=-2.066, p=0.039) was observed in the brain of Tg APPsw treated with anatabine compared to untreated Tg APPsw littermates (Fig. 10).",
      "citation": {
        "type": "PubMed",
        "reference": "23178521"
      },
      "annotations": {
        "Species": {
          "10090": true
        },
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "source": 24,
      "target": 22,
      "key": "7a3d6eae411ea47b187657c205f382e251fb0ea43992fb95659575d187e33754330411c12f48805dd270b18cf6c0013628fe581f99b1e7ba47043cc2a06531f7"
    }
  ]
}